Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

INSANE: Looking into cue biopharma s return on capital employed - The Real Truth

According to data from Benzinga Pro, during Q4, Cue Biopharma's (NASDAQ:CUE) reported sales totaled $8.25 million. Despite a 35.47% increase in earnings, the company posted a loss of $8.38 million. Cue Biopharma collected $2.40 million in revenue during Q3, but reported earnings showed a $12.99 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.